



Canertinib (dihydrochloride)

Catalog No: tcsc0263

Available Sizes
Size: 10mg
Size: 50mg
Size: 100mg
Size: 200mg
Specifications
CAS No: 289499-45-2
Formula: C ₂₄ H ₂₇ Cl ₃ FN ₅ O ₃
Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Target: EGFR;EGFR
Purity / Grade: >98%
Solubility: 10 mM in DMSO
Alternative Names: Canertinib;CI-1033 dihydrochloride;PD-183805 dihydrochloride
Observed Molecular Weight: 558.86



Product Description

Canertinib dihydrochloride (CI-1033;PD-183805) is a potent and irreversible **EGFR** inhibitor; inhibits cellular **EGFR** and **ErbB2** autophosphorylation with IC_{50} s of 7.4 and 9 nM.

IC50 & Target: IC50: 7.4 nM (EGFR), 9 nM (ErbB2)[1]

In Vitro: Canertinib significantly inhibits growth of cultured melanoma cells, RaH3 and RaH5, in a dose-dependent manner. IC $_{50}$ is approximately 0.8 μ M and by 5 μ M both cell lines are completely growth-arrested within 72 h of treatment. Incubation of exponentially growing RaH3 and RaH5 with 1 μ M canertinib accumulated the cells in the G1-phase of the cell cycle within 24 h of treatment without induction of apoptosis. 1 μ M canertinib inhibits ErbB1-3 receptor phosphorylation with a concomitant decrease of Akt-, Erk1/2- and Stat3 activity in both cell lines^[2].

In Vivo: Canertinib shows superior *in vivo* antitumor activity, giving growth delays in A431 xenografts exceeding 50 days following oral administration^[1]. The growth of human malignant melanoma xenografts, RaH3 and RaH5, in nude mice is significantly inhibited by i.p. injections of 40 mg/kg/day canertinib (Fig. 4). The anti-proliferative effect on melanoma xenografts is visible already within 4 days of treatment and further increased throughout the treatment period as observed through the differences in tumor volumes, reaching statistical significance within 18 days of treatment^[2].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!